Close Menu

NEW YORK (GenomeWeb) – Liquid biopsy test developer OncoCyte announced today its public offering of about 9.3 million shares of its common stock at $3.75 per share for gross proceeds of approximately $35 million.

The company has also granted the underwriters a 30-day option to purchase up to an additional 1.4 million shares of common stock at the public offering price to cover any overallotments.

Piper Jaffray is acting as the sole book-running manager and Janney Montgomery Scott is acting as the comanager for the offering, which should close on or about February 12.   

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.